Company Revenue

The company's 3Q22 orthopedic revenue grew more than 20% but changes to viscosupplement reimbursement will be a headwind through 1H23....

The company grew below 1% in 3Q22 due to a difficult prior year comparison, supply chain headwinds and slowly recovering...

The company grew more than 18% in 3Q22 and will benefit from substantial CMS fee increases in ASCs for 2023....

The company grew in high single-digits for 3Q22 on the strength of case volume recovery and its portfolio of procedural...

The company grew by more than 52% in 3Q22, spurred by accelerating contributions from its direct sale force....

The company grew over 28% in 3Q22, as new product introductions attract new surgeons and drive sales force expansions....

The company's MACI product grew nearly 30% in the third quarter of 2022, but patient flow disruptions brought a guidance...

The company grew just over 10% in third quarter of 2022, driven by competitive rep conversions and robotic pull-through....

The company grew over 40% in 3Q22, driven by its accelerating lateral surgery business and enabling technologies like EOS....

Excluding the impact of foreign currency, the company grew in the mid-single digits as elective procedures recovered in the U.S....